<DOC>
	<DOCNO>NCT01311622</DOCNO>
	<brief_summary>The purpose study determine whether fostamatinib influence plasma concentration warfarin change blood thin effect , investigate safe tolerable administer warfarin .</brief_summary>
	<brief_title>Effects Administration Fostamatinib Blood Concentrations Warfarin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Provision inform consent prior study specific procedure ( include genotyping screen sample CYP2C9 VKORC1 ) . Males female ( nonchildbearing potential ) age 18 55 year ( inclusive ) Subjects must negative occult blood ( stool card ) prior administration . Body weight least 50 kg body mass index ( BMI ) 18 35 kg/m2 inclusive History clinically significant disease disorder , opinion Investigator , may put subject risk participation study , influence result study . Healthy subject predict sensitive warfarin base CYP2C9 VKORC1 genotype . A protein C and/or protein S deficiency . Absolute neutrophil count less 2500/mm3 2.5 x 109/L Previous treatment warfarin clinical indication ( ie , participation previous warfarin interaction study acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>drug-drug interaction</keyword>
	<keyword>Phase 1</keyword>
	<keyword>healthy subject</keyword>
	<keyword>warfarin</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>fostamatinib open-label</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>level Warfarin blood</keyword>
</DOC>